A phase I/II trial of paclitaxel, carboplatin, and gemcitabine in untreated patients with advanced non-small cell lung cancer

被引：0

作者：

Kelly, K

Mikhaeel-Kamel, N

Pan, ZX

Murphy, J

Prindiville, S

Bunn, PA

机构：

[1] Univ Colorado, Hlth Sci Ctr, Ctr Canc, Div Med Oncol, Denver, CO 80262 USA

[2] Univ Colorado, Ctr Canc, Lung Canc Program, Denver, CO 80262 USA

[3] Univ Colorado, Ctr Canc, Dept Prevent Med & Biostat, Denver, CO 80262 USA

来源：

CLINICAL CANCER RESEARCH | 2000年 / 6卷 / 09期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Paclitaxel and carboplatin is widely used in the treatment of patients with advanced non-small cell lung cancer (NSCLC); however, median survival remains <1 year. One strategy to improve survival is to add a third active drug with a differing mechanism of action. Gemcitabine is a novel antimetabolite with considerable activity in NSCLC. The primary objective of this Phase I/II study was to determine the maximally tolerated dose of gemcitabine administered with fixed doses of paclitaxel and carboplatin in untreated patients with advanced NSCLC.

引用

页码：3474 / 3479

页数：6

共 50 条

[21] Phase I/II trial of docetaxel and carboplatin in previously untreated patients with advanced non-small-cell lung cancer
Shoji A.
Ogura T.
Suzuki K.
Takahashi H.
Takahashi K.
Yoshiike Y.
Watanuki Y.
Nishiyama H.
Toda M.
Odagiri S.
International Journal of Clinical Oncology, 2000, 5 (5) : 323 - 327
[22] Phase II trial of ixabepilone and carboplatin with or without bevacizumab in patients with previously untreated advanced non-small cell lung cancer
Shipley, D.
Spigel, D. R.
Burris, H. A., III
Waterhouse, D. M.
Webb, C. D.
Gian, V.
Hart, L. L.
Greco, F. A.
Hainsworth, J. D.
JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
[23] Phase I/II study of carboplatin and weekly paclitaxel for advanced non-small cell lung cancer.
Ohashi, N
Arita, KI
Daga, H
Mito, A
Nishino, R
Moritani, C
Nakamura, K
Daido, K
JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 687S - 687S
[24] Phase I/II dose finding study of paclitaxel and carboplatin in advanced non-small cell lung cancer
Scagliotti, GV
Crinó, L
Pozzi, E
Corgna, E
Selvaggi, G
Novello, S
Salsano, G
Gentile, A
Palladino, M
Marracolo, F
Tonato, M
LUNG CANCER, 1999, 25 (01) : 39 - 46
[25] Preliminary results of a phase I/II clinical trial of paclitaxel and carboplatin in non-small cell lung cancer
Natale, RB
SEMINARS IN ONCOLOGY, 1996, 23 (06) : 51 - 54
[26] Preliminary results of a phase I/II clinical trial of paclitaxel and carboplatin in non-small cell lung cancer
Natale, RB
SEMINARS IN ONCOLOGY, 1996, 23 (05) : 2 - 6
[27] Phase II randomized trial of vinorelbine and gemcitabine versus carboplatin and paclitaxel in advanced non-small-cell lung cancer
Lilenbaum, RC
Chen, CS
Chidiac, T
Schwarzenberger, PO
Thant, M
Versola, N
Lane, SR
ANNALS OF ONCOLOGY, 2005, 16 (01) : 97 - 101
[28] A phase I/II study of bexarotene with carboplatin and weekly paclitaxel for the treatment of patients with advanced non-small cell lung cancer
Dragnev, Konstantin H.
Whyman, Jeremy D.
Hahn, Cynthia K.
Kebbekus, Peter E.
Kokko, Sarah F.
Bhatt, Sunil M.
Rigas, James R.
JOURNAL OF THORACIC DISEASE, 2018, 10 (09) : 5531 - 5537
[29] A PHASE I/II STUDY OF BEXAROTENE WITH WEEKLY PACLITAXEL AND CARBOPLATIN FOR THE TREATMENT OF PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER
Whyman, Jeremy D.
Kebbekus, Peter E.
Fink, Sarah K.
Rigas, James R.
Dragnev, Konstantin H.
JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S883 - S883
[30] Phase II study of carboplatin and weekly paclitaxel in advanced non-small cell lung cancer
Nakadate, Megumi
Yamazaki, Koichi
Konishi, Jun
Kinoshita, Ichiro
Sukoh, Noriaki
Harada, Masao
Akie, Kenji
Ogura, Shigeaki
Ishida, Takashi
Munakata, Mitsuru
Dosaka-Akita, Hirotoshi
Isobe, Hiroshi
Nishimura, Masaharu
ANTICANCER RESEARCH, 2006, 26 (5B) : 3767 - 3772

← 1 2 3 4 5 →